PubMed Health⌕ Search

Biomedical subjects

W Rösch

Publications and source records attributed to W Rösch.

348 records · Page 20Linked to original sources
PubMedDate not supplied

[The aging gastrointestinal tract--diseases of the gastrointestinal tract in old age].

Gastrointestinal symptoms in geriatric patients are not necessarily due to disorders of the gut or even consequence of aging. The high capacity in regard to motoric phenomena, secretion and absorption prevents deficiency syndromes. The spectrum of geriatric gastrointestinal diseases does not differ from the one seen in the normal population except of the increasing rate of malignancies. Multimorbidity and consecutive polypragmasy may be responsible for iatrogenic disorders of the gastrointestinal tract.

Aged↗
PubMedDate not supplied

[NSAID-induced ulcers--therapy and prevention].

There is a lot of epidemiological information to calculate the risk of developing gastroduodenal lesions during NSAID therapy on a reliable base in an individual patient. In treating NSAID ulcers one has to decide whether the antirheumatic treatment can be stopped or whether one has to continue. In the first mentioned condition all antiulcer drugs can be used safely like in chronic recurrent ulcer disease. However, when NSAID therapy has to be continued proton pump inhibitors are necessary in doubled therapeutic dosage. Prophylaxis should not be made in all patients on NSAIDs, but is only indicated with convincing cost-benefit ratio in high-risk patients. Whereas H2-blockers and proton pump inhibitors seem to protect mainly the duodenal mucosa oral prostaglandins (Misoprostol) are effective in the stomach as well.

Adult↗
PubMedDate not supplied

Chronic functional dyspepsia: short- and medium-term outcome of a therapeutic trial with cisapride.

In an open, multicenter trial, 329 patients (who attended gastroenterology practices or outpatient gastroenterology departments of hospitals) with a mean age of 47.3 years, received 5 mg of cisapride three times a day (TID) for at least 2 weeks for the treatment of persistent, recurring symptoms of functional dyspepsia. The patients' symptoms required investigation or were unresponsive to previous drug treatment. When necessary, the dose of cisapride was increased to 10 mg TID, in most patients after 1 week of treatment, and the duration of therapy was extended to 4 weeks. At the end of cisapride treatment, the most frequently reported symptoms of functional dyspepsia were significantly improved. At the onset of the trial, 72.3% of patients complained of a moderate-to-severe feeling of fullness; this decreased to 19.7% after 2 weeks of treatment and to 15.3% after 4 weeks. The symptoms of bloating, a feeling of heaviness in the stomach, and postprandial epigastric discomfort showed similar improvement. Overall, 43.6% of patients were symptom-free or almost symptom-free after 1 week of cisapride treatment, 69.6% after 2 weeks, and 71.5% after 4 weeks. Only 11% of patients needed the increased dose of cisapride. Six weeks after completion of the trial, 74 patients (22.5%) had recurrent symptoms of functional dyspepsia. Adverse experiences were noted in 74 patients (22.5%), most commonly loose stools (7.6% of all patients), fatigue (4.9%), and headaches (4.0%). In most cases, these adverse experiences were mild and transient in nature and led to premature discontinuation of treatment in 11 patients (3.3%).(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMedDate not supplied

Endogenous motilin and lower esophageal sphincter pressure in man: clue to an association.

In man (n = 5), after intraduodenal instillation of 50 ml of 0.1 N hydrochloric acid the lower esophageal sphincter pressure (LESP) and plasma motilin concentrations rise concomitantly exceeding basal by about 80% (p less than 0.025) and 90% (p less than 0.05), respectively, at 3 to 4 minutes. These results suggest that the increase in LESP after duodenal acidification may be brought about by endogenously released motilin.

Adult↗